Affiliation:
1. Department of Dermatology, Katihar Medical College, Katihar, Bihar, India
Abstract
Background:
Tildrakizumab is an interleukin-23p19 inhibitor, approved by the Food and Drug Administration for the management of moderate-to-severe plaque psoriasis.
Purpose:
This review aims to describe the dermatological implications and applications of tildrakizumab.
Methods:
PubMed and Google Scholar were searched for scholarly articles related to tildrakizumab and its utility in dermatology using the search terms “Tildrakizumab” AND “Psoriasis” AND “other dermatological disorders.”
Results:
Tildrakizumab is a valuable biologic agent for the management of psoriasis. It has also been successfully used for other dermatologic disorders such as hidradenitis suppurativa, lichen planus, pityriasis rubra pilaris, lupus erythematosus tumidus, and pyoderma gangrenosum.
Conclusion:
Tildrakizumab’s usage is not limited to psoriasis. Its benefit extends to many more dermatologic conditions. Besides, it has an acceptable safety profile.
Reference71 articles.
1. Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: Evidence to date;Beck;Psoriasis (Auckl),2018
2. Tildrakizumab: First global approval;Markham;Drugs,2018
3. The role of IL-23 in the immunopathogenesis of psoriasis;Di Meglio;F1000 Biol Rep,2010
4. Interleukin-23: As a drug target for autoimmune inflammatory diseases;Tang;Immunology,2012
5. Interleukin-23: A key cytokine in inflammatory diseases;Duvallet;Ann Med,2011